Neptune Wellness Solutions Inc. (NEPT) and MyoKardia Inc. (NASDAQ:MYOK) Comparing side by side

We will be comparing the differences between Neptune Wellness Solutions Inc. (NASDAQ:NEPT) and MyoKardia Inc. (NASDAQ:MYOK) as far as institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neptune Wellness Solutions Inc. N/A 0.00 N/A -0.07 0.00
MyoKardia Inc. 33.56M 63.21 67.70M -1.59 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 shows Neptune Wellness Solutions Inc. and MyoKardia Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neptune Wellness Solutions Inc. 0.00% 0% 0%
MyoKardia Inc. -201.73% -19.9% -17.2%

Analyst Recommendations

In next table is given Neptune Wellness Solutions Inc. and MyoKardia Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Neptune Wellness Solutions Inc. 0 0 0 0.00
MyoKardia Inc. 0 0 1 3.00

Competitively MyoKardia Inc. has an average target price of $85, with potential upside of 61.57%.

Insider & Institutional Ownership

Institutional investors held 17.69% of Neptune Wellness Solutions Inc. shares and 92.4% of MyoKardia Inc. shares. About 23.43% of Neptune Wellness Solutions Inc.’s share are held by insiders. Comparatively, 0.6% are MyoKardia Inc.’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Neptune Wellness Solutions Inc. -4.63% 3.86% 8.36% -14.63% 43.44% 37.8%
MyoKardia Inc. 14.82% 23.78% -14.83% -13.92% -14.35% 4.83%

For the past year Neptune Wellness Solutions Inc. was more bullish than MyoKardia Inc.

Summary

Neptune Wellness Solutions Inc. beats MyoKardia Inc. on 6 of the 10 factors.

Neptune Technologies & Bioressources Inc., a nutrition products company, focuses on providing nutrition solutions, including specialty ingredients and consumer brands. The company develops solutions available in various delivery forms. It also offers various specialty ingredients, including premium krill oil and other marine oils, as well as seed oils. The company sells its premium krill oil under the OCEANO3 brand directly to consumers through oceano3.com in Canada and the United States. In addition, Neptune Technologies & Bioressources Inc. is pursuing opportunities in the prescription drug markets, through its subsidiary, Acasti Pharma Inc., that focuses on the research, development, and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia. The company was founded in 1925 and is headquartered in Laval, Canada.

MyoKardia, Inc., a clinical stage biopharmaceutical company, engages in discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is MYK-461, an orally-administered small molecule that is in Phase II clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy (HCM). The company also develops MYK-491, an orally-administered small molecule that treats genetic dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart. In addition, it develops HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients; DCM-2, a product candidate that is intended to increase cardiac muscle contractility to normal levels in genetic DCM patients through a different mechanism than that of MYK-491; and LUS-1, a product candidate, which is intended to counteract a muscle disruption that results in impaired relaxation of the heart. The company has a strategic collaboration with Sanofi S.A. for the research, development, and commercialization of pharmaceutical products to treat, prevent, and diagnose HCM and DCM, as well as additional indications. MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.